Novo Nordisk (CPH: NOVO-B) stock: the official figures
Novo Nordisk (NOVO NORDISK A/S) is listed on Nasdaq Copenhagen under the ticker NOVO-B and belongs to the health care sector. In fiscal 2025 it reported revenue of DKK 309,064m and a net profit of DKK 102,434m, according to the annual accounts it filed with the regulator.
Identifiers for Novo Nordisk: ISIN DK0062498333 · LEI 549300DAQ1CVT6CXN342.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | DKK 309,064m | DKK 290,403m | +6.4% |
| Operating profit | DKK 127,658m | DKK 128,339m | −0.5% |
| Net profit | DKK 102,434m | DKK 100,988m | +1.4% |
| Earnings per share | DKK 23.06 | DKK 22.67 | +1.7% |
| Operating margin | 41.3% | 44.2% | −2.9 pts |
| Net margin | 33.1% | 34.8% | −1.6 pts |
| Total assets | DKK 542,902m | DKK 465,795m | +16.6% |
| Equity | DKK 194,047m | DKK 143,486m | +35.2% |
| Cash | DKK 26,464m | DKK 15,655m | +69.0% |
| Operating cash flow | DKK 119,102m | DKK 120,968m | −1.5% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
7 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | DKK 309,064m | DKK 127,658m | DKK 102,434m | DKK 23.06 | Annual report |
| 2024 | DKK 290,403m | DKK 128,339m | DKK 100,988m | DKK 22.67 | Annual report |
| 2023 | DKK 232,261m | DKK 102,574m | DKK 83,683m | DKK 18.67 | Annual report |
| 2022 | DKK 176,954m | DKK 74,809m | DKK 55,525m | DKK 24.51 | Annual report |
| 2021 | DKK 140,800m | DKK 58,644m | DKK 47,757m | DKK 20.79 | Annual report |
| 2020 | DKK 126,946m | DKK 54,126m | DKK 42,138m | DKK 18.05 | Annual report |
| 2019 | DKK 122,021m | DKK 52,483m | DKK 38,951m | DKK 16.41 | — |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Novo Nordisk. Year by year: dividends paid.
Dividends
In fiscal 2025, Novo Nordisk paid DKK 51,763m in dividends, 50.5% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | DKK 51,763m | 50.5% |
| 2024 | DKK 44,140m | 43.7% |
| 2023 | DKK 31,767m | 38.0% |
| 2022 | DKK 25,303m | 45.6% |
| 2021 | DKK 21,517m | 45.1% |
| 2020 | DKK 20,121m | 47.8% |
| 2019 | DKK 19,409m | 49.8% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about Novo Nordisk
- How much did Novo Nordisk earn in fiscal 2025?
- Novo Nordisk reported a net profit of DKK 102,434m for fiscal 2025, on revenue of DKK 309,064m. The year before it reported a net profit of DKK 100,988m.
- Does Novo Nordisk pay a dividend?
- In fiscal 2025, Novo Nordisk paid DKK 51,763m in dividends, 50.5% of its net profit, according to its cash flow statement.
- What are the earnings per share of Novo Nordisk?
- They were DKK 23.06 in fiscal 2025, compared with DKK 22.67 the year before.
- Where is Novo Nordisk listed?
- Novo Nordisk is listed on Nasdaq Copenhagen under the ticker NOVO-B and belongs to the health care sector.
- What is the ISIN of Novo Nordisk?
- The ISIN of Novo Nordisk is DK0062498333, the international code that identifies its shares. Its LEI, the legal entity identifier, is 549300DAQ1CVT6CXN342.
- Where do the figures for Novo Nordisk come from?
- From the report Novo Nordisk files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the report Novo Nordisk files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.